Form 4: Eli Lilly Director Acquires Shares Under Deferral Plan

J. Erik Fyrwald, a director at Eli Lilly & Co, acquired 13.358 shares of common stock at $742.35 per share under the company's Directors' Deferral Plan.

Summary

• On January 21, 2025, J. Erik Fyrwald, a director of Eli Lilly & Co, acquired 13.358 shares of common stock.
• The acquisition was made at a price of $742.35 per share.
• These shares were acquired in lieu of cash compensation under the Lilly Directors' Deferral Plan.
• The acquired shares have been deferred as stock units and will be settled in shares of common stock following Fyrwald's separation from service.
• Following the transaction, Fyrwald directly owns 72,671.552 shares of Eli Lilly & Co common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. A director acquiring shares signals confidence, but it's part of a pre-existing compensation plan, so it's not a surprise.

Positives

• The director's participation in the Directors' Deferral Plan demonstrates confidence in the company's future performance.
• The acquisition increases the director's stake in the company, aligning his interests with those of other shareholders.

Future Outlook

The acquired shares will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

Directors acquiring shares in their own companies is generally viewed positively by the market, as it signals confidence in the company's prospects. Deferred compensation plans are a common way for companies to align the interests of directors with those of shareholders.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder sentiment.

Key Dates